NCT06006260

Brief Summary

The purposes of this study are to explore the trajectory of symptom distress and balance ability in patients with rectal cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
107

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 17, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 23, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

November 20, 2023

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2026

Completed
Last Updated

March 20, 2026

Status Verified

March 1, 2026

Enrollment Period

2.2 years

First QC Date

August 17, 2023

Last Update Submit

March 18, 2026

Conditions

Rectal Cancer

Outcome Measures

Primary Outcomes (1)

  • Self-report Questionnaire

    Show the specific trajectory of LAR Syndrome, psychological distress, fecal incontinence-related QoL, and balance ability based on different tumor locations in patients with rectal cancer

    Change from baseline symptom at 2 months

Eligibility Criteria

Age20 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Rectal cancer patients during therapy.

You may qualify if:

  • Newly diagnosed rectal cancer
  • Patients already know their condition.
  • Aged 20 years and older.
  • Consciously communicate in Mandarin or Taiwanese.
  • Agreed with the interview and had signed the permit.

You may not qualify if:

  • Recurrent rectal cancer.
  • KPS of patients less than 80

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chung Gung University

Taoyuan, Kwei-Shan Dist., 333, Taiwan

Location

MeSH Terms

Conditions

Rectal Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesIntestinal DiseasesRectal Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 17, 2023

First Posted

August 23, 2023

Study Start

November 20, 2023

Primary Completion

January 31, 2026

Study Completion

January 31, 2026

Last Updated

March 20, 2026

Record last verified: 2026-03

Locations

TW(1)